Caribou Biosciences, Inc.
CRBU
$0.7331
-$0.046-5.90%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -41.62% | -91.45% | -7.75% | -30.64% | -3.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.62% | -91.45% | -7.75% | -30.64% | -3.63% |
| Cost of Revenue | -4.52% | 4.33% | 33.87% | 31.42% | 21.54% |
| Gross Profit | -0.24% | -464.75% | -40.74% | -41.21% | -25.75% |
| SG&A Expenses | 7.89% | -38.82% | 13.49% | 64.36% | 13.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.58% | -6.61% | 28.24% | 39.90% | 19.64% |
| Operating Income | -2.22% | -130.56% | -32.35% | -47.84% | -22.45% |
| Income Before Tax | -3.46% | -246.77% | -27.70% | -47.03% | -27.46% |
| Income Tax Expenses | -104.66% | -- | -- | -- | 175.71% |
| Earnings from Continuing Operations | -2.85% | -246.77% | -27.70% | -47.03% | -27.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.85% | -246.77% | -27.70% | -47.03% | -27.85% |
| EBIT | -2.22% | -130.56% | -32.35% | -47.84% | -22.45% |
| EBITDA | -1.06% | -149.43% | -32.23% | -48.37% | -22.05% |
| EPS Basic | 0.23% | -221.11% | 13.17% | -0.74% | 11.80% |
| Normalized Basic EPS | 0.99% | -179.49% | 13.47% | -0.80% | 11.88% |
| EPS Diluted | 0.23% | -221.11% | 13.17% | -0.74% | 11.80% |
| Normalized Diluted EPS | 0.99% | -179.49% | 13.47% | -0.80% | 11.88% |
| Average Basic Shares Outstanding | 3.09% | 7.96% | 47.09% | 45.95% | 44.97% |
| Average Diluted Shares Outstanding | 3.09% | 7.96% | 47.09% | 45.95% | 44.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |